Literature DB >> 9507818

Multifocal renal cell carcinoma in Japanese patients with tumors with maximal diameters of 50 mm. or less.

K Gohji1, I Hara, A Gotoh, H Eto, H Miyake, T Sugiyama, H Okada, S Arakawa, S Kamidono.   

Abstract

PURPOSE: We determined the risk of local recurrence in 64 Japanese patients a median of 69 years old with renal cell carcinoma who were possible candidates for nephron sparing surgery and who underwent radical nephrectomy.
MATERIALS AND METHODS: A total of 64 kidneys in which tumors 50 mm. or less were resected were prospectively examined pathologically in 3 mm. sections. The incidence of satellite tumors and the relationship between the pathological findings of the primary and satellite tumors were evaluated.
RESULTS: Satellite tumors were identified in 10 of the 64 kidneys (15.6%), a rate similar to that reported in the United States. The correlation of histological findings between primary and satellite tumors was 70% for tumor grade. Satellite tumor grade was less than that of the primary lesion in 3 cases. In 60% of the specimens with multifocal renal cancer satellite tumors were within 10 mm. of the margin of the primary tumor. At this distance, if partial nephrectomy had been performed, the satellite lesions would have been missed in 4 of these 10 patients (40%). Of the 10 kidneys with satellite renal tumors 8 (80%) had vascular invasion of the primary tumor. Multiple logistic regression analysis demonstrated that vascular invasion was a significant predictor of multifocality of renal cell carcinoma.
CONCLUSIONS: Our results suggest that vascular invasion is a risk factor for multifocality in Japanese patients with renal cell carcinoma. Therefore, careful and long-term followup is necessary in patients with renal cell carcinoma who have undergone nephron sparing surgery, especially those with vascular invasion of the primary tumor.

Entities:  

Mesh:

Year:  1998        PMID: 9507818

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

2.  Gross intraoperative evaluation (GIE): a reliable method for the evaluation of surgical margins at partial nephrectomy.

Authors:  Hasan Yilmaz; Seyfettin Ciftci; Levend Ozkan; Ali Saribacak; Kursat Yildiz; Ozdal Dillioglugil
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 3.  Renal cell carcinoma.

Authors:  Paul Cairns
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

4.  Double partial nephrectomy in a patient with two adenocarcinomas in a solitary kidney.

Authors:  A Giannopoulos; G Kyriakou; C Constantinides; T Manousakas; A Kyroudi; C Dimopoulos
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

5.  Tumor enucleation specimens of small renal tumors more frequently have a positive surgical margin than partial nephrectomy specimens, but this is not associated with local tumor recurrence.

Authors:  Lu Wang; Ian Hughes; Connor Snarskis; Helyn Alvarez; Jingyang Feng; Gopal N Gupta; Maria M Picken
Journal:  Virchows Arch       Date:  2016-10-24       Impact factor: 4.064

6.  Critical histologic appraisal of the pseudocapsule of small renal tumors.

Authors:  Lu Wang; Jingyang Feng; Helyn Alvarez; Connor Snarskis; Gopal Gupta; Maria M Picken
Journal:  Virchows Arch       Date:  2015-06-19       Impact factor: 4.064

Review 7.  Oncological outcomes of partial nephrectomy for tumours larger than 4 cm: A systematic review.

Authors:  Tarek H El-Ghazaly; Ross J Mason; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2014-01       Impact factor: 1.862

8.  Staged, open, no-ischemia nephron-sparing surgery for bilateral-multiple kidney tumors in a patient with birt-hogg-dubé syndrome.

Authors:  Ahmet Tefekli; Ayşe Deniz Akkaya; Kamil Peker; Terman Gümüş; Metin Vural; Fatin Cezayirli; Ahmet Musaoglu; Tarık Esen
Journal:  Case Rep Med       Date:  2012-04-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.